Back

Cardiovascular safety of metformin and sulfonylureas in patients with different cardiac risk profiles

27 August 2016 (00:00 - 00:00)
Organised by:
Congress Presentation Part of: Cancer and cardiotoxicity: from bench to bedside Cardiotoxicity of drugs ESC Premium Access ESC Congress 2016

About the speaker

Photo
Doctor Raphael Wurm

Medical University of Vienna, Vienna (Austria)

6 More presentations in this session

Presentation thumbnail
Enhanced-autophagy by exenatide mitigates doxorubicin-induced cardiotoxicity in vitro and in vivo
Miss H. Cho (Seoul, KR)
Abstract
Presentation thumbnail
TCTP down-regulation induced cardiac cell death through Bnip3 may be a pivotal mechanism of Doxorubicin-induced heart failure
Ms W. Cai (Guangzhou, CN)
Abstract
Presentation thumbnail
CCAAT/enhancer binding protein delta contributes to an earlier phase of pro-inflammatory response in doxorubicin related cardiomyopathy
Professor P. Liu (Tainan, TW)
Abstract
Presentation thumbnail
Cardioprotective effect of taurine against doxorubicin cardiotoxicity in rats: echocardiographic and histologic study
Doctor V. Baris (Gaziantep, TR)
Presentation thumbnail
Protective effect of clusterin on doxorubicin induced myocardial damage
Associate Professor J. Lee (Goyang, KR)
Abstract Slides

Access the full session

Session thumbnail
Cancer and cardiotoxicity: from bench to bedside

The Event

Event poster

ESC Congress 2016

27 August - 31 August 2016

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources